A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity
- PMID: 18172313
- DOI: 10.1158/0008-5472.CAN-07-0669
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity
Erratum in
- Cancer Res. 2008 Jul 15;68(1):6030
Abstract
PTEN and the pan phosphoinositide 3-kinase (PI3K) inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1 benzopyran-4-one (LY294002) exert significant control over tumor-induced angiogenesis and tumor growth in vivo. The LY294002 compound is not a viable drug candidate due to poor pharmacologic variables of insolubility and short half-life. Herein, we describe the development and antitumor activity of a novel RGDS-conjugated LY294002 prodrug, termed SF1126, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment, resulting in enhanced delivery of the active compound to the tumor vasculature and tumor. SF1126 is water soluble, has favorable pharmacokinetics, and is well tolerated in murine systems. The capacity of SF1126 to inhibit U87MG and PC3 tumor growth was enhanced by the RGDS integrin (alpha v beta 3/alpha 5 beta 1) binding component, exhibiting increased activity compared with a false RADS-targeted prodrug, SF1326. Antitumor activity of SF1126 was associated with the pharmacokinetic accumulation of SF1126 in tumor tissue and the pharmacodynamic knockdown of phosphorylated AKT in vivo. Furthermore, SF1126 seems to exhibit both antitumor and antiangiogenic activity. The results support SF1126 as a viable pan PI3K inhibitor for phase I clinical trials in cancer and provide support for a new paradigm, the application of pan PI3K inhibitory prodrugs for the treatment of cancer.
Similar articles
-
Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.Cancer Chemother Pharmacol. 2015 Mar;75(3):595-608. doi: 10.1007/s00280-014-2639-x. Epub 2015 Jan 13. Cancer Chemother Pharmacol. 2015. PMID: 25578041
-
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.Cancer Chemother Pharmacol. 2011 Aug;68(2):325-35. doi: 10.1007/s00280-010-1486-7. Epub 2010 Oct 24. Cancer Chemother Pharmacol. 2011. PMID: 20972874 Free PMC article.
-
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.Mol Cancer Ther. 2016 Nov;15(11):2553-2562. doi: 10.1158/1535-7163.MCT-15-0976. Epub 2016 Aug 5. Mol Cancer Ther. 2016. PMID: 27496136 Free PMC article.
-
Current prodrug design for drug discovery.Curr Pharm Des. 2009;15(19):2236-50. doi: 10.2174/138161209788682523. Curr Pharm Des. 2009. PMID: 19601825 Review.
-
ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.Acta Pharmacol Sin. 2010 Sep;31(9):1189-97. doi: 10.1038/aps.2010.150. Epub 2010 Aug 23. Acta Pharmacol Sin. 2010. PMID: 20729870 Free PMC article. Review.
Cited by
-
Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions.Mol Cancer. 2024 Aug 10;23(1):164. doi: 10.1186/s12943-024-02072-1. Mol Cancer. 2024. PMID: 39127670 Free PMC article. Review.
-
Combined Deep Learning and Molecular Modeling Techniques on the Virtual Screening of New mTOR Inhibitors from the Thai Mushroom Database.ACS Omega. 2023 Oct 2;8(41):38373-38385. doi: 10.1021/acsomega.3c04827. eCollection 2023 Oct 17. ACS Omega. 2023. PMID: 37867669 Free PMC article.
-
Metabolic Interventions in Tumor Immunity: Focus on Dual Pathway Inhibitors.Cancers (Basel). 2023 Mar 29;15(7):2043. doi: 10.3390/cancers15072043. Cancers (Basel). 2023. PMID: 37046703 Free PMC article. Review.
-
Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.Pharmaceutics. 2023 Feb 16;15(2):664. doi: 10.3390/pharmaceutics15020664. Pharmaceutics. 2023. PMID: 36839989 Free PMC article. Review.
-
Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities.Cancers (Basel). 2022 Aug 20;14(16):4028. doi: 10.3390/cancers14164028. Cancers (Basel). 2022. PMID: 36011021 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials